Abstract: High throughput technologies have the potential to affect all aspects of drug discovery. Considerable attention is paid to high throughput screening (HTS) for small molecule lead compounds. The identification of the targets that enter those HTS campaigns had been driven by basic research until the advent of genomics level data acquisition such as sequencing and gene expression microarrays. Large-scale profiling approaches (e.g., microarrays, protein analysis by mass spectrometry, and metabolite profiling) can yield vast quantities of data and important information. However, these approaches usually require painstaking in silico analysis and low-throughput basic wet-lab research to identify the function of a gene and validate the gene product as a potential therapeutic drug target. Functional genomic screening offers the promise of direct identification of genes involved in phenotypes of interest. In this review, RNA interference (RNAi) mediated loss-of-function screens will be discussed and as well as their utility in target identification. Some of the genes identified in these screens should produce similar phenotypes if their gene products are antagonized with drugs. With a carefully chosen phenotype, an understanding of the biology of RNAi and appreciation of the limitations of RNAi screening, there is great potential for the discovery of new drug targets.
INTRODUCTION

RNA Interference
The identification of RNA interference (RNAi) in C. elegans [1] initiated a large research effort to define the biological role and mechanism of action of RNAi. RNAi pathways are widely conserved, and likely evolved as a means of defense against viral invaders or genomic parasites such as transposons [2] . RNAi is a sequence-specific process for silencing gene expression at the post-transcriptional level ( Fig. 1 ) [3] [4] [5] [6] . In brief, double stranded RNA (dsRNA) in cells is processed into small interfering RNAs (siRNAs) by a ribonuclease called DICER. One of the siRNA strands enters and guides the RNA-induced silencing complex (RISC) to bind to and then cleave a complementary mRNA. Silencing of gene expression also occurs at the translational level when RISC carries a guide strand that does not have perfect complementarities with the mRNA. These messages are sequestered in P-bodies and usually subsequently degraded [6] . RNAi is one example of the increasingly complex RNAbased regulatory network that includes many different types of non-coding RNAs (ncRNAs) [7, 8] . These ncRNAs include long ncRNAs, transfer RNA (tRNA), ribosomal RNA (rRNA), small nucleolar RNA (snoRNA), as well as the microRNA (miRNA), and Piwi-interacting RNA (piRNA) varieties involved in RNAi. Exogenous reagents introduced into cells to initiate the RNAi pathway are often referred to as triggers.
RNAi Libraries
The demonstration that RNAi was effective in mammalian cells [9] ushered in a new era for mammalian somatic cell genetics. For the first time, it became relatively *Address correspondence to this author at the Lead Discovery Department, Amgen Inc., ASF1-2118, 1120 Veterans Blvd., South San Francisco, CA 94080, USA; Tel: 650-244-2184; E-mail: pkassner@amgen.com straightforward to perform loss-of-function testing in mammalian cells. As siRNA design rules were identified and improved [10] [11] [12] [13] , the creation of libraries targeting genes in any sequenced mammalian genome gave us the exciting opportunity to elucidate gene function on an unprecedented scale. Several different library configurations are now available commercially, through collaboration, or for in-house production. The selection of a library type will depend on the resources available and the challenges of the biological system of interest.
Synthetic siRNA and Endoribonuclease Prepared siRNA
Synthetic siRNAs are available from multiple vendors (Ambion, Dharmacon, Invitrogen, IDT, Sigma, and Qiagen), and many of them sell libraries of siRNAs to sets of genes of interest (e.g. GPCRs, kinases, "druggable genome" up to whole genome). The specifics of the products differ by vendor, with various lengths and modifications, number of individuals and/or pools, validated or merely predicted siRNAs being available. Many vendors offer a variety of formats (concentrations, quantities and plate layouts) for the convenience of the user. For the do-it-yourself labs, there are a number of online tools for the design of siRNAs against your genes of interest [14] .
Endoribonuclease prepared siRNA (esiRNA) has been shown to be an effective method of generating pools of siRNAs for gene knockdown [15] . In this method, a polymerase chain reaction (PCR) product is generated so that in vitro transcription products can be generated in both directions. These RNAs are hybridized to form long dsRNA that is then cleaved with RNAse III into small fragments. By incorporating rules for design of individual siRNAs, new algorithms can select PCR primers that will amplify gene specific regions with a greater propensity to generate effective siRNAs [16] . The group that developed these new algorithms has provided an online resource for whole genome targeted esiRNAs http://cluster-12.mpi-cbg.de/bioinformatics_group/ RiDDLE.html. Fig. (1) . Mechanism of RNAi. RNA interference is initiated when dsRNA is introduced into the cell. Long dsRNA or shRNAs are processed by the ribonuclease DICER into siRNAs (21-23bp long). DICER will aid loading of the siRNA into the RNA induced silencing complex (RISC). Direct introduction of siRNA into cells will not require DICER activity and siRNAs will load straight into RISC. A single strand of RNA known as the guide strand will remain bound to RISC and dictate the binding to a target mRNA. Perfect complementarity will result in site-specific cleavage of the target mRNA. Mismatches in the base-pairing will result in translational repression and eventual degradation of mRNA in P-bodies. This ability of mismatched sequence to silence gene expression can result in off-target effects of RNAi triggers.
The effectiveness of both siRNA and esiRNA is good, with most design algorithms resulting in >70% knockdown for about 80% of siRNA designs. The maximal extent of knockdown is somewhat transcript dependent and appears to be independent of the type of siRNA designed [16] . The duration of the knockdown effect is limited to 5-7 days in most cell types, with peak knockdown between 2-5 days [17, 18] . The loss of effect is likely due to dilution of the siRNA in daughter cells, since siRNA delivery to non-dividing cells has been shown to knock down message for several weeks [19] . The timing for maximal protein knockdown depends on the turnover of protein product of the target mRNA, with peak knockdown coming earlier for proteins with shorter half-lifes [20] .
Delivery remains the biggest issue for both siRNA and esiRNA. Despite the availability of dozens of lipid, amine and peptide-based formulations on the market [14] , it is still often difficult to identify a reagent that will effectively deliver siRNA to certain cell types. Many primary cell types, hematopoietic and neuronal cell lines remain resistant to high efficiency transfection. Electroporation remains an option for delivery into these cell types, but currently this is restricted to 96-well plate technology (Amaxa, Bio-Rad, BTX) so the throughput of screens would be limited. For researchers who plan screens in difficult-to-transfect cell types, alternative approaches (described below) may be required.
Vector-Based RNAi
When long-term knockdown of a gene-product is desired or when difficult to transfect cell types must be used for screening, transfection of synthetic siRNA or esiRNA will not yield satisfactory results. Vector-based RNAi, especially when delivered by viral vectors, can solve both of these issues. Adenoviral [21] , retroviral [22, 23] and lentiviral vectors [24, 25] have been used for the creation of large RNAi libraries which are available commercially or through collaboration. The choice of library will depend on how the properties of the virus correspond with the intended use (dividing vs non-dividing cells, presence of viral receptors, in vivo vs in vitro use, etc.). In addition to the type of virus that is to be used, the features of the library itself should be considered.
Short Hairpin RNA
The most common types of vector-based RNAi are the short hairpin RNAs (shRNA). Typically 50-60 nucleotides in length, shRNAs are transcribed under the control of RNA polymerase III (pol III) promoters. They form stem-loop structures and are transported to the cytoplasm where the loop is cleaved by the nuclease DICER. The resulting dsRNA then enters the RISC as an siRNA. Greater understanding of the endogenous microRNA (miRNA) pathway has lead to the use of hairpins modeled on miRNAs (shRNAmir) driven by pol II promoters. Longer transcripts with imperfect pairing form structures that mimic primary miRNAs. These are first processed in the nucleus by the nuclease Drosha, then in the cytoplasm by DICER. Evidence suggests that loading of RISC and subsequent gene regulation is more efficient when DICER directs the RNA into RISC [26] . While shRNAs and shRNAmirs can be as effective as siRNAs at knocking down target genes, the algorithm development for selection of effective hairpin sequences is not as advanced as that for selection of siRNAs. As a result, when large libraries are constructed, many of the individual clones may have poor efficacy even if the sequence has been verified. Knockdown via shRNAs and shRNAmirs can attain similar levels (>70% reduction) but in a lower percentage of constructs [~40% [27] ; ~50%, personal data; 20-47%, (http://cgap.nci.nih.gov/RNAi/Table_2)].
Dual Promoter dsRNA Expression
As an alternative to expression of a single-stranded transcript that will fold to produce dsRNA, opposing promoters can be used to produce both sense and anti-sense transcripts from the same DNA. This method has been used by several labs to create vectors capable of producing dsRNA inside cells [28] [29] [30] . Depending on the length of the dsRNA, it will either be cleaved by DICER or enter RISC directly. This approach has been adapted for the creation of specialty li-braries. In a novel approach, a library of partially randomized consensus sequences was designed to target all members of the nuclear hormone receptor family. As a proof of concept, the investigators identified receptors involved in amyloid degradation [31] . The dual promoter approach was also utilized to create a library of RNAi triggers targeting embryonic stem (ES) cell specific transcripts. ES cDNA libraries were inserted between opposing promoters and screened for genes essential for self renewal [32, 33] . RNAi triggers derived from this method have not been extensively validated, so the average effectiveness of these RNAi triggers is unknown. However, each of these studies demonstrates the creative use of a basic technology and the potential for expansion beyond libraries designed around known genomic annotations. Approaches like these could allow the discovery of previously unknown transcripts as well as identify their functions.
RNAi SCREENING
Due to the early availability of large libraries and the ease of introducing dsRNA into Drosophila cells, many large scale screens have been performed, published and reviewed [64] [65] [66] [67] [68] [69] . Initially, RNAi from long dsRNA in Drosophila cells was thought not to be subject to the same off-target effects as in mammalian cell systems. However, more recent analysis suggests that off-target effects remain an issue and need to be considered during library design and interpretation of data [70] . Therefore, genes identified in Drosophila screens with long dsRNA require the same level of confirmation and validation as those identified in mammalian screens with siRNA or shRNA. Because of the ease of screening by simple feeding or soaking and the ability to observe the whole organism, multiple screens have also been performed , (and reviewed in [108, 109] ) in model organisms such as C. elegans. Although a thorough, detailed analysis has not been published, data suggests that off-target effects are also observed in C. elegans with as little as 14 base pair match to target mRNA [110] and therefore caution is advised when interpreting data from these screens as well. (See Sidebar for details of off-target effects). The number of large-scale mammalian cell screens [22, 24, 25, 27, 29, is smaller than in the other model organisms and many of these have been included in previous reviews [133] [134] [135] [136] [137] [138] [139] [140] . High throughput genomic loss-of-function screens with RNAi can take two basic forms, arrayed screening and pooled library selections. Each of these is discussed below.
Sidebar: Off-Target Effects of RNAi
As initially described and outlined above, RNAi is a sequence-specific process of silencing genes. Algorithm development aided by wet-lab validation of siRNA sequences has advanced to the point where effective RNAi triggers are easy to obtain. However, use of RNAi comes with the challenge of managing the unintended consequences of delivering dsRNA to cells. There are two primary sources of off-target effects.
It has been clearly demonstrated that many cells can activate an innate immune response to dsRNA. The dsRNA-activated protein kinase (PKR) initiates a signaling cascade resulting in changes in expression of a large number of interferon responsive genes [141, 142] . This effect is cell type dependent (not all cells exhibit such widespread effects), and dose-dependent. Although chemical modification of siRNAs can reduce the activation of PKR [143] , these modifications will not be available for vector-based RNAi. Analysis of sequences has identified motifs that accentuate the interferon responses to RNAi [144, 145] . New algorithms can remove these interferon response stimulating sequences from consideration when designing RNAi triggers, thus reducing the chance of stimulating this pathway.
The other source for off-target effects of RNAi triggers is sequence-specific and a natural consequence of RNAi biology. Perfect matches of triggers with mRNAs other than the intended target can be excluded by bioinformatic filtering. However, due to the biology of the RNAi machinery, most of these exogenous triggers can also silence unintended mRNAs. The RNAi machinery has co-evolved with endogenous microRNAs (miRNAs), which have the potential to silence hundreds of genes. An miRNA entering the RISC could result in either the sitespecific cleavage of a target mRNA or the repression of translation from that mRNA depending on the makeup of the RISC and the degree of complementarity to the message (Fig. 1) . The rules for determining which messages are silenced by a given miRNA sequence are still being resolved, but it is clear that short stretches of perfect complementarity in the seed region (bases 2-7 or 2-8) are sufficient for silencing [146, 147] . Because a match of 6-7 bases is adequate for silencing, design of exogenous RNAi triggers will carry the chance of suppressing translation of unintended mRNAs. This unintentional gene silencing can result from either the sense or anti-sense strand of the siRNA. Significantly for RNAi-based screening, these off-target effects often result in phenotypic consequences. In one study nearly 30% of randomly chosen siRNA duplexes resulted in altered viability in transfected cell lines, and this did not correlate with genespecific silencing activity [148] . It is currently difficult to predict the actual mRNAs modulated by the off-target effects of a given RNAi trigger; however many groups are actively developing predictive algorithms (reviewed by Rajewsky [149] ). Off-target effects are responsible for a large degree of noise in RNAi screening campaigns and have lead to the false identification of genes in many pathway screens [70] . Importantly, the phenotypic changes monitored in an RNAi screen can be determined to be on-or off-target effects with careful follow-up. Once determined to be an off-target effect, it is possible to determine the actual mRNA targets of the RNAi triggers [131, 150] .
Pooling of multiple siRNAs targeted against the same gene has been proposed to increase (http://www.ambion. com/techlib/tn/121/11.html) or decrease (http://www. dharmacon.com/docs/article_pooling.pdf) off-target effects. Pooling of multiple siRNAs targeting the same mRNA has the potential advantage to lower the number of wells assayed during primary screening (as compared to multiple individual siRNAs). For screens of reasonable cost in laboratories with high throughput capacity, the use of pools in primary screening can delay the ability to obtain validated results (deconvolution of pools is required to demonstrate that multiple siRNA against the same gene result in the same phenotype). However, expensive or difficult low-throughput screens can greatly benefit from the initial use of well-designed pooled siRNAs.
For the synthetic siRNAs, there is hope that modifications of bases in the duplex can modulate which strand is incorporated into RISC, and reduce the number of offtarget effects [151, 152] . Newly available reagents combine design, modifications and pooling in attempt to reduce off-target effects to very low levels.
Continued advances in understanding and reducing off-target effects will promote adoption and acceptance of RNAi screening. Until new generations of RNAi reagents are widely available, careful interpretation and rigorous follow-up of RNAi screening results will be essential.
Arrayed Screening
Arrayed screening is the most common form of RNAi screening. Typically, each RNAi trigger is represented in a spatially-defined position, such as a well of a microtiter plate. Virus, plasmid, or siRNA is delivered to cells well-bywell via infection or transfection. Following incubation (typically 24-96 hours), a phenotype of interest is measured ( Fig. 2A) . Due to the nature of high throughput screens, most RNAi screens are run as standard homogeneous end-point assays. Microtiter plate-based screens are particularly well suited to this type of assay given the development of liquid handlers, robotic equipment and multimode readers designed for standard small molecule library screening. As long as RNAi triggers can be delivered to the cell line of interest, virtually any cell-based assay can be converted to an arrayed RNAi screen including cell viability/proliferation, apoptosis, protein secretion/processing (immunoassay), transcriptional reporter assays, cell motility, glucose transport and even quantitative PCR to measure transcriptional changes of endogenous genes. High content image analysis is becoming increasingly popular in RNAi screening given the ability to monitor multiple parameters in a single experiment [153] . This greatly expands the power of RNAi to ascertain gene function.
Originally developed as a means to screen cDNAs [154] , transfected cell microarrays are seeing increased use for screening RNAi libraries. This technique makes use of microarray spotters to create arrays of RNAi triggers on microscope slides (Fig. 2B) . Long dsRNA uptake [54] , siRNA transfection [155, 156] and viral infection [157] have been demonstrated on microarray slides. A significant advantage of microarray based RNAi screening is the decrease in cost due to the reduced volume of all reagents. Because all RNAi triggers are in a single vessel, homogeneous "lyse, mix and read" type assays will not work and these arrays are limited to image-based screens [153, 158] . Live cell time-resolved imaging will further enhance the power of this technology as it applies to RNAi screening [156] . These screens require specialized equipment (e.g. microarray spotters, microscopes, microarray scanners), are technically challenging and are limited by currently available endpoints. However, they will surely find their place in high throughput functional genomic screening.
Pool-Based Library Selections
Assessment of large libraries in a single experiment has the potential to greatly increase the number and throughput of large scale analyses that can be performed. In this type of experiment, a library of RNAi triggers is introduced into a population of cells and the population is placed under some type of selective pressure. The cells remaining after that selection are analyzed for the complement of RNAi that confers the selected phenotype (Fig. 3) . Libraries are often created to contain molecular barcodes, with each trigger paired with a unique DNA barcode that can be used for subsequent identification. Commonly applied to cell survival, comparison of multiple populations can extend simple survival assays to identify genes involved in susceptibility to treatments [121] , comparison of genotypic variation [24] , or comparison of distinct cancer subgroups [114] . This Darwinian selection can be modified to include growth phenotypes such as colony formation or growth in soft agar [24, 128, 130, 159] . Conceivably, pool-based screens could be applied to a wide range of phenotypes that don't confer growth advantages, but instead allow physical selection such as fluorescence activated cell sorting (FACS) for expression of fluorescent reporters and FACS or magnetic bead isolation for receptor expression increase/decrease. Once populations of cells of the correct phenotype are isolated, the population is analyzed for the RNAi component. Sequencing of shRNA or associated barcodes, as well as microarray analysis of barcodes can be used to determine which RNAi triggers are over-or under-represented in the population. Selections from pooled RNAi triggers compels the use of plasmid/viral based libraries since siRNA (e.g. synthetics, esiRNAs, etc) itself would be difficult to isolate and identify given the high level of endogenous small RNAs present in cells. In addition to the issues facing standard RNAi screens, pool-based selections have several additional hurdles. Because multiple triggers in a single cell could confound the outcome by increasing chances for combinatorial effects or result in bystander effects, transfection or infection of cells needs to be optimized so that each cell will only contain a single type of trigger. Due to the greater inconsistency involved in pooled selections (resulting from the inequality in viral/plasmid preparation, and the infection/transfection variability), there is need for more extensive replication or consecutive iterative rounds of transduction and selection to determine which genes have the real and most dramatic effect on a particular phenotype. Also in question is the size of the library that can be examined by pooled selection. As the number of triggers increases from hundreds to thousands in a single sample, the power to detect enrichment or loss of any single trigger will decrease. However, as shRNA libraries with higher knockdown efficiencies are built and disseminated to the scientific community, the use of pool-based selections will likely increase.
THE PERIL AND THE PROMISE
Verification of RNAi Experiments
There are several good publications that will guide the user on the experimental design, choice of reagents, use of controls as well as provide tools for data normalization and analysis [160] [161] [162] [163] [164] [165] . However, even with proper experimental design and execution as well as stringent statistical analysis, RNAi screening is subject to both false positive and false negative events. Given the propensity for off-target effects of RNAi (see Sidebar and review by Echeverri [160] ), a simple evaluation of screening data will yield many false positive hits. Verification that RNAi-mediated knockdown of the intended target gene is causing the phenotype is accomplished in several ways. The two best methods for verification are rescue and redundancy (reviewed in Echeverri et al. [166] ). Expression of a functional version of the gene of interest (modified to remove the target of the RNAi trigger) is used to rescue the RNAi-induced phenotype and demonstrate that the phenotype is target-specific. Although fairly definitive, this method is used infrequently due to the difficulty in generating modified cDNAs for multiple target genes. A simpler approach is to take advantage of multiple silencing reagents to demonstrate that the phenotype in question is not due to off-target effects of an individual RNAi trigger. This redundancy approach can easily be applied to follow up of an HTS of an RNAi library. Many laboratories perform initial screens with multiple triggers for each gene, so that a certain level of redundancy is built into the primary screen. It is common to screen with four individual triggers and require that at least two influence the desired phenotype before calling a gene a hit. Secondary screening usually involves testing four new independent triggers. Redundancy at the assay level (reagents, cell line, endpoint, etc.) is also important to demonstrate that hits are specific to the pathway/phenotype in question and not a result of an assay artifact. When done properly, most of the false positives that result from high throughput RNAi screening can be quickly eliminated so that one can concentrate on the truly interesting genes.
False Negatives in RNAi Screening
A potentially significant limitation to RNAi screening are false negatives, i.e. genes that are actually involved in a phenotype of interest may not be identified in an RNAi screen. Incomplete knockdown of a target gene is one of the main reasons for these false negatives. The trigger type (siRNA vs shRNA), the efficacy of the designed sequence, the delivery Fig. (3) . Pooled RNAi screening. Through viral infection or plasmid transfection, a small library of RNAi triggers is delivered to cells in a pool. In the example shown, an inducible shRNA library is used. The pool is split and expression of the shRNAs is induced in one of the subpools. Each subpool is subjected to selective pressure (e.g. stressful growth conditions, drug treatments, etc.). Following growth in culture, each population of cells is harvested, and then barcodes are retrieved by PCR and analyzed by microarray. Increased representation of a barcode in the induced subpool compared to the un-induced subpool indicates that the corresponding shRNA was selected for (suggesting that target gene expression was unfavorable for growth conditions). Decreased representation of the barcode indicates that the corresponding shRNA was selected against (suggesting that target gene expression was advantageous for growth conditions). mechanism, the normal mRNA and protein turnover rates as well as the existence of feedback mechanisms can all affect the extent of knockdown of any given gene. However, it is clear that most RNAi triggers do not eliminate 100% of the target message (and consequently the target protein). Many proteins will need very high levels of knockdown before they elicit a phenotype. In whole animal developmental studies, it is clear that expression hypomorphs (e.g. many heterozygous knockouts) often have enough protein to remain normal. When series of hypomorphic alleles are tested, normal phenotypes are often observed until an expression threshold is crossed and an abnormal phenotype is observed. Once this threshold is crossed, many genes show a dose dependence in their ability to control phenotypes, with decreasing levels resulting to increasingly severe phenotypes [167] [168] [169] [170] [171] [172] [173] . Interestingly, an allelic series of the cell cycle checkpoint protein Hus1 demonstrated dose-dependent effects in vitro, but little effect in vivo [174] . For some genes the protein expression must be reduced to quite low levels before a phenotype is observed. Erbb2 hypomorphs at 10% of normal levels remain developmentally normal, while further reduction results in perinatal lethality [175] . Cell lines made hypomorphic for Orc2 at 10% of normal levels are viable, but have a defect in the G1>S-phase transition in the cell cycle [176, 177] . This suggests that RNAi experiments designed to look at simple viability may have overlooked the involvement of Orc2, while careful cell cycle analysis might have identified Orc2 with potent RNAi triggers. An example of this has been shown with the hypomorphic series produced with RNAi against p53. Both in vitro and in vivo data suggest that low-level knockdown of p53 has limited effect in most assays, while more complete knockdown scores in most assays. Intermediate levels of p53 knockdown will affect the phenotypic readout in some assays, while not in others [178] . A PLK1 hypomorphic series generated with RNAi demonstrated similar expression level dependent phenotypic effects in vitro [179] . Extrapolation of these data to larger library screening suggests that, depending on the assay readout, genes could be missed in primary screening or not verified by redundant RNAi triggers because of incomplete knockdown.
Redundancy can also explain why legitimate drug targets known to be involved in a particular phenotype might not be identified in an RNAi screen. A small molecule drug may modulate multiple isoforms of a protein, or act on closely related gene products, whereas RNAi would target only one. Gene duplication is a common event during evolution. When retained, duplicated genes gradually change in both sequence and sub-function, but because of similarities, one paralog may remain able to perform an activity in the absence of the other. Both gene-targeting and in vitro experiments tell us that functional redundancy is common in many multi-gene families of proteins [180] [181] [182] [183] [184] [185] [186] [187] [188] [189] . This has been demonstrated by the use of RNAi as well. Simultaneous use of RNAi triggers against multiple targets allows the interrogation of the function of potentially redundant genes. This was first demonstrated with related phosphatases in Drosophila neural development [190, 191] . An analysis of differentially expressed genes in Drosophila wing disc demonstrated that only 2 of 8 genes knocked down by RNAi resulted in phenotypic changes even though all eight of those genes showed phenotypes when overexpressed. The two genes with RNAitriggered phenotypes were unique in the Drosophila genome, while most of the others had other family members expressed in the same tissue at the same time, suggesting that functionally redundant paralogs precluded identification of the target genes by RNAi [192] . In a Drosophila screen for cell-cycle regulators, combinations of RNAi triggers to groups of paralogs failed to identify additional genes that were not identified as individuals [193] . However, in this study the effective use of increasing numbers of different dsRNA had not been demonstrated. Redundancy between gene duplicates has been systematically studied in C. elegans by feeding combinations of RNAi triggers to both duplicates (corresponding to single genes in S. cerevisiae or Drosophila genomes). In this study, 11% of duplicate pairs had pheno-types in combination, but not as individuals. This is likely to be an underestimate given the calculated rate of false negatives (50%) in their screen [194] . Screening of all possible combinations of genes (even in pairs) is currently not tenable. However, the thoughtful combination of RNAi triggers to close paralogs may yield information on genetic redundancy and lead to pairs of targets for future drug discovery efforts. Closely related proteins may be amenable to targeting with a single small molecule, and thus further efforts in combinatorial RNAi are warranted.
Target Identification
False positives through off-target effects could impose limitations on the efficiency of RNAi screens because of the potentially extensive follow-up and additional validation required. However, an understanding of the necessary quality control and proper hit selection procedures, coupled with systematic confirmation, can reduce time and effort spent following false leads. False negatives due to incomplete knockdown and redundancy do impose boundaries on what targets RNAi screening will uncover. Nevertheless, it is possible that the targets that are identified through RNAi screens will be among the best targets for pharmacological intervention. These targets are likely to be key nodes and have little redundancy in pathways of interest; therefore they are likely to have meaningful biological effect when perturbed. Because targets that do not require complete inhibition to produce a biological effect should be preferentially identified, it is possible that dosage of drugs could be reduced or titrated to produce the intended outcome in patients. One caveat to this is the potential for finding targets that have multiple functions, with only selected functions inhibited by pharmacological intervention. For example, many kinases contain domains that act as adaptors to facilitate protein complex formation. RNAi-mediated inhibition of such a kinase could result in a phenotypic alteration, whereas an enzymatic inhibitor of the same kinase may not yield a similar result.
It is clear that high throughput RNAi screens in their many forms will continue to provide information about basic biological systems. It is also likely that these screens will become even more significant in the unearthing of novel targets for drug discovery. In addition to the verification required by use of RNAi, these new targets will still need the same rigorous validation at multiple levels as targets identified through other means. With the proper caution, RNAi can be a robust target discovery tool, one which combines the power of genetic manipulation with the scale of high throughput technologies.
